Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H30N5O10P.C4H4O4 |
Molecular Weight | 635.5149 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.CC(C)OC(=O)OCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=CN=C2N)OCOC(=O)OC(C)C
InChI
InChIKey=VCMJCVGFSROFHV-WZGZYPNHSA-N
InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1
Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
VIREAD (AUTHORIZED: HEPTATITS B, CHRONIC)
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
||
|
NCI_THESAURUS |
C97452
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/14/1419
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
EVIPLERA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
||
|
FDA ORPHAN DRUG |
538416
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
ATRIPLA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
||
|
FDA ORPHAN DRUG |
559316
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
TRUVADA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.1
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
VIREAD (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
202138-50-9
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | |||
|
m10559
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | Merck Index | ||
|
63717
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | |||
|
322248
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | RxNorm | ||
|
DTXSID5050426
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | |||
|
TENOFOVIR DISOPROXIL FUMARATE
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | Description: White to almost-white, crystalline powder. Solubility: Slightly soluble in water, soluble in methanol, very slightly soluble in dichloromethane. Category: Antiretroviral (Nucleotide Reverse Transcriptase Inhibitor). Storage: Tenofovir disoproxil fumarate should be kept in a tightly closed container, protected from light and stored at a temperature between 2?8 ?C. Additional information: Tenofovir disoproxil fumarate may exhibit polymorphism. Definition: Tenofovir disoproxil fumarate contains not less than 98.5% and not more than 101.0% of tenofovir disoproxil fumarate(C19H30N5O10P,C4H4O4), calculated with reference to the anhydrous substance. Manufacture: The production method is validated to ensure that the substance, if tested, would comply with: ? a limit of not more than 5 ppm for the mutagenic impurity 9-propenyladenine (impurity K), which may be a synthesis related substance, using a suitable method; ? a limit of not more than 1.0% for the tenofovir disoproxil (S)-enantiomer (impurity G) using a suitable chiral chromatographic method. | ||
|
OTT9J7900I
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | |||
|
C47747
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | |||
|
SUB12607MIG
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | |||
|
100000092141
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | |||
|
6398764
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | |||
|
63718
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | |||
|
KK-89
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | |||
|
DBSALT000172
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | |||
|
1643656
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | |||
|
OTT9J7900I
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | |||
|
CHEMBL1538
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY | |||
|
7165
Created by
admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD